NASDAQ:UNCY Unicycive Therapeutics Q1 2025 Earnings Report $5.33 -0.03 (-0.58%) As of 03:13 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Unicycive Therapeutics EPS ResultsActual EPS-$0.50Consensus EPS -$1.40Beat/MissBeat by +$0.90One Year Ago EPSN/AUnicycive Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUnicycive Therapeutics Announcement DetailsQuarterQ1 2025Date5/14/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time8:00AM ETUpcoming EarningsUnicycive Therapeutics' Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Unicycive Therapeutics Earnings HeadlinesUNCY SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsJuly 6 at 8:00 PM | globenewswire.comBragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the FirmJuly 2, 2026 | globenewswire.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.July 7 at 1:00 AM | Weiss Ratings (Ad)Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing DeficienciesJuly 2, 2026 | finance.yahoo.comUNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudJuly 1, 2026 | businesswire.comUNCY ALERT: Unicycive Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Encouraged to Contact the FirmJuly 1, 2026 | globenewswire.comSee More Unicycive Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email. Email Address About Unicycive TherapeuticsUnicycive Therapeutics (NASDAQ:UNCY), a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.View Unicycive Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles GE Vernova’s Power Surge Turns the Grid Into an AI Trade2 Short Squeezes for Summer Speculation: What the Bears Are Getting WrongBig Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term InvestorsMarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponVisa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
